5 December 2011
Clarity Pharmaceuticals has been awarded two Commercialisation Australia grants totalling $300,000. The “Skills and Knowledge” and “Proof of Concept” grants will help Clarity provide its PET imaging agents and services for human clinical studies, and aid in Clarity’s diagnostic development program. The funding will directly contribute to a clinical trial validating one of Clarity’s products for imaging, and will represent the first clinical use of Clarity’s imaging agents.
Clarity’s proprietary imaging agents produce the best results for PET imaging of biopharmaceuticals as they are built for the radioisotope copper-64. Due to its 13 hour half-life, copper-64 delivers high-resolution images and accurate biodistribution data over 24-48 hours, ideal for imaging biopharmaceutical drug candidates.
Regulatory bodies increasingly require more localisation, clearance and mechanism of action data for new drugs. Clarity’s technology can help companies developing biopharmaceuticals find this information and more for their drug candidates. The increasing interest in targeted imaging for biopharmaceuticals makes Clarity’s technology a breakthrough for this growing area of pharmaceutical development.
About Commercialisation Australia
Commercialisation Australia is a hands-on assistance program delivered by the Australian government. Their support is driven towards helping products or services with high potential to enter the market. For further information please visit: http://www.commercialisationaustralia.gov.au
About Clarity Pharmaceuticals
Clarity Pharmaceuticals is a private, Sydney-based company focused on developing PET radiopharmaceuticals. It offers chelators for research, has an imaging service and runs an in-house diagnostic development program. Clarity has access to world-class technology, infrastructure and researchers in the field of nuclear medicine.
